NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the New Drug Application for neoadjuvant therapy of Anitumab (KN026) co‑developed with Alphamab Oncology in combination with the Group’s self‑developed Docetaxel (Albumin‑Bound) for Injection (HB1801) for adult patients with early or locally advanced HER2‑positive breast cancer has been accepted by NMPA and included in the priority review and approval procedure. A pivotal Phase III study demonstrated that the combination regimen significantly improved the overall pathological complete response rate versus current standard‑of‑care treatment.
NewTimeSpace News: China Shengmu Organic Milk Limited (01432.HK) announced that due to non‑compliance with the minimum public float requirement under Listing Rule 13.32B and the condition of severe shortfall in public float under Listing Rule 13.32F, the stock short name will be changed to “CHINASHENGMU‑PF” in English and “中国圣牧‑PF” in Chinese, effective from 9:00 a.m. on 5 August 2026. The stock code “1432” remains unchanged. The suffix will be removed once the Company re‑complies with relevant requirements.
NewTimeSpace News: Liu Chong Hing Investment announced on August 4 that Zeng dian ke , Co-Chief Executive Officer of the Company, has been appointed by the Board as Executive Director, effective 4 August 2026.
NewTimeSpace News: Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that its self‑developed candidate HX9428 has obtained US‑FDA IND clearance to commence Phase II clinical trial for neovascular age‑related macular degeneration (nAMD). Meanwhile, the Company has officially launched its second Phase II clinical study (CTR20262884) of HX9428 for nAMD in China, adopting a head‑to‑head positive‑control design against aflibercept.
NewTimeSpace News: ALLAN INTERNATIONAL HOLDINGS announced on August 4 that as at the date of the announcement, the company’s public float stood at 24.04%, still below the minimum 25% requirement stipulated under the Listing Rules. The Board is considering adopting a share scheme and expects to formulate a detailed recovery plan before the end of the third quarter of 2026.
NewTimeSpace News: Changan Minsheng Logistic announced on August 4 that for the six months ended 30 June 2026, revenue is expected to range from RMB4.45 billion to RMB4.6 billion, representing a year-on-year increase of roughly 6.89% to 10.5%; net profit attributable to owners of the Company is projected at RMB20 million to RMB25 million, a year-on-year decrease of approximately 39.73% to 51.78%.
NewTimeSpace News: Truly International Holdings Limited (00732.HK) announced that the Group’s unaudited consolidated net turnover for July 2026 stood at approximately HK$1.259 billion, representing a decrease of around 14.2% compared with HK$1.468 billion for the corresponding period in 2025. For the seven‑month period ended 31 July, cumulative consolidated net turnover totalled approximately HK$8.224 billion, a drop of roughly 14% versus HK$9.566 billion in the same period of last year.
NewTimeSpace News: SKYWORTH GROUP announced on August 4 that the unaudited profit after tax for the six months ended 30 June 2026 is expected to increase by no less than 170% compared with the same period last year.
NewTimeSpace News: Zhongshi Minan Holdings Limited (08283.HK) announced that Ms. Wu Mengmeng has resigned as Executive Director and member of the Nomination Committee with effect from 4 August 2026, to devote more time and energy to other business commitments. Non‑executive Director Ms. Gao Song has been appointed as member of the Nomination Committee, effective on the same date.
NewTimeSpace News: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (00874.HK) announced that its subsidiary Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. has received the revised Drug Production Licence approved and issued by Guangdong Provincial Drug Administration. Approval is granted for the removal of the production site “Qixinggang, Nancun Town, Panyu District, Guangzhou” together with corresponding workshop production lines, and the production person‑in‑charge is changed from “Ye Bin” to “Yang Chao”. The licence is valid until 29 March 2030.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that the New Drug Application (NDA) for TQB3909 Tablets, a Class‑1 innovative BCL‑2 inhibitor independently developed by its subsidiary Chia‑Tai Tianqing, has been accepted by CDE under NMPA. The drug is indicated for adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy including a BTK inhibitor. The candidate was granted priority review status in July 2026.
NewTimeSpace News: The Securities and Futures Commission of Hong Kong issued an announcement regarding highly‑concentrated shareholding in DESUN SERVICES (02270.HK). Inquiry results showed that as at 21 July 2026, 18 shareholders collectively held 33.04% of shares. Together with the controlling shareholders’ 66.49% stake, their aggregate holding accounted for 99.53% of the issued share capital, while public shareholders held merely 0.47%. The Company’s share price surged 92.3% from 2 July to 21 July.
NewTimeSpace News: TS Wonders Holding Limited (01767.HK) announced that the Board of Directors has resolved to change the use of remaining proceeds from its initial public offering. Approximately HK$5.70 million of unused funds will be reallocated to the purchase of plant premises and equipment to expand production capacity for existing nut and potato‑chip product lines, supporting sustained business growth.
NewTimeSpace (newtimespace.com) reported that on August 4, 2026, the chip theme strengthened, with ASMPT (00522.HK) fluctuating higher. As of 13:24, the stock was quoted at HKD 156.300, up 3.99%.
NewTimeSpace (newtimespace.com) reported that on August 4, 2026, the robotics theme continued to strengthen, while Xiaomi-W (01810.HK) fluctuated lower. As of 13:17, the stock was quoted at HKD 27.600, down 1.29%.
NewTimeSpace News: August 04, 2026, HORIZON CD(09930.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 4.02 billion, decreased by 7.49% YoY
